These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17331230)

  • 21. Twenty-year trends in benzodiazepine dispensing in the Australian population.
    Islam MM; Conigrave KM; Day CA; Nguyen Y; Haber PS
    Intern Med J; 2014 Jan; 44(1):57-64. PubMed ID: 24450521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription opioid dispensing in Australian children and adolescents: a national population-based study.
    Bell J; Paget SP; Nielsen TC; Buckley NA; Collins J; Pearson SA; Nassar N
    Lancet Child Adolesc Health; 2019 Dec; 3(12):881-888. PubMed ID: 31604614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dispensing patterns of emergency medicines prescribed by Australian dentists from 1992 to 2018 - a pharmacoepidemiology study.
    Park JS; Kruger E; Tennant M
    Int Dent J; 2020 Aug; 70(4):254-258. PubMed ID: 32170731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dispensing patterns of medicines prescribed by Australian dentists from 2006 to 2018 - a pharmacoepidemiological study.
    Park JS; Page AT; Kruger E; Tennant M
    Int Dent J; 2020 Aug; 71(2):106-12. PubMed ID: 32856305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
    McRae I; van Gool K; Hall J; Yen L
    Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
    Donges E; Staatz CE; Benham H; Kubler P; Hollingworth SA
    Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moral hazard and prescription medicine use in Australia--the patient perspective.
    Doran E; Robertson J; Henry D
    Soc Sci Med; 2005 Apr; 60(7):1437-43. PubMed ID: 15652677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to biologicals in Crohn's disease in ten European countries.
    Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
    World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.
    Hopkins AM; Proudman SM; Vitry AI; Sorich MJ; Cleland LG; Wiese MD
    Med J Aust; 2016 Feb; 204(2):64-8. PubMed ID: 26821102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines.
    Boyadzieva VV; Stoilov N; Stoilov RM; Tachkov K; Kamusheva M; Mitov K; Petrova GI
    Front Pharmacol; 2018; 9():794. PubMed ID: 30072903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribing patterns of analgesics and other medicines by dental practitioners in Australia from 2001 to 2012.
    Hollingworth SA; Chan R; Pham J; Shi S; Ford PJ
    Community Dent Oral Epidemiol; 2017 Aug; 45(4):303-309. PubMed ID: 28251672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)].
    Rubio-Terrés C; Ordovás Baines JP; Pla Poblador R; Martínez Nieto C; Sánchez Garre MJ; Rosado Souvirón MA; Sierra Muñoz A; Sánchez Mateo M;
    Farm Hosp; 2007; 31(2):78-92. PubMed ID: 17590116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Australian Bushfires on Asthma Medicine Prescription Dispensing.
    Zhu Z; Naunton M; Mortazavi R; Bushell M
    Healthcare (Basel); 2024 Feb; 12(4):. PubMed ID: 38391803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.